secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYOMO, INC. (MYO)
CIK:        0001369290
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091801
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myomo Q2 2024 revenue $7.5M (+77% product revenue); record 213 MyoPro orders
----------------------------------------------------------------------------

- Product revenue $7.5M (+77% YoY); total revenue $7.5M (+26% YoY) reflecting prior-year license fee.
- Record 213 MyoPro authorizations/orders (+70% YoY); backlog 282 units (+58% YoY).
- 1,179 patients in pipeline (+22% YoY); 550 new candidates added in Q2 (+35% YoY).
- Gross margin 70.8% (product GM up 1,030 bps to 70.8%); net loss $1.1M ($0.03 EPS).
- Q3 revenue guidance $8.0-8.5M; FY2024 revenue target $28-30M; targeting Q4 operating cash flow breakeven.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369290/000095017024091801/0000950170-24-091801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369290/000095017024091801/myo-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer